GOLGA6L2

Across TCGA pan-cancer cohorts, GOLGA6L2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GOLGA6L2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GOLGA6L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6L2 expression acts as an unfavorable survival marker.

LUSC, LIHC, and UCEC are the cancer types where GOLGA6L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.011	0.684	<.001	12	view →
LIHC	OS	Median	All	0.118	0.783	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	OS	Median	II,III,IV	0.306	0.707	.008	3	view →
BRCA	OS	Median	All	0.817	0.963	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GOLGA6L2–LUSC (OS)

Open the LUSC breakdown →